China Resources Boya Bio-pharmaceutical Group Co.,Ltd

China Resources Boya Bio-pharmaceutical Group Co., Ltd. is a manufacturing company listed on the Shenzhen Stock Exchange since 2012. The company is primarily focused on the development and production of blood products, positioning itself as a key player in the biopharmaceutical industry. It adheres to a strategic goal of becoming a world-class provider of blood products while also maintaining a presence in the biochemical and chemical drug sectors. The company's main business lines include the research, development, and sales of blood products such as albumin, immunoglobulin, and coagulation factors. Additionally, it operates in the field of biochemical drugs, with a focus on peptide drugs and other therapeutic areas, including orthopedics and immunomodulation. Boya Xinhe, a subsidiary established in 2014, specializes in anti-infective and cardiovascular drugs, although it has faced challenges in achieving large-scale production. The company also has a pharmaceutical sales division, Anhui Greenke, which has developed a strong market presence through an efficient sales network.

The company has always focused on the development strategy of "becoming a world-class blood products" and insists on focusing on blood products. The company has the following core competencies: (1) Shareholder Resource Endowment and Management Empowerment The actual controller the company, China Resources Group, is an approved state-owned capital investment company by the State-owned Assets Supervision and Administration Commission of the State Council, with a business covering six major fields: major consumption, comprehensive energy, urban construction and operation, major health, industrial finance, technology and emerging industries. In 2024, China Resources's total assets reached 2.71 trillion yuan, achieving operating income of 932.66 billion yuan and a total profit of 9264 billion yuan. China Resources Group ranked 67th on the 2025 Fortune Global 500. The company's controlling shareholder, China Pharmaceutical, is a leading large pharmaceutical group company in China, ranking among the top three in the industry. Since China Resources Pharmaceutical took control of the company, it has given the company support and empowerment in all aspects, such as strategic management, organizational optimization, talent introduction, risk management and the docking of government resources, laying a solid foundation for the companys long-term and stable development. (2) Clear Strategic Planning The company will always adhere to the strategic goal of "becoming a world-class blood products enterprise and focus on the main business of blood products, and continue to promote the healthy and rapid development of the blood products business. (3) Excellent Plasma Station Expansion andasma Collection Capability The company is one of the few blood products enterprises in the country that has a full range of three products and the qualification to expand plasma stations. It is one of the very few blood products enterprises that have the resource endowment of central enterprises. After China Resources Group became the actual controller of the company, it has given strong support in plasma station application, resource docking, plasma station operation and other aspects. In terms of existing plasma stations, by taking measures such as standardization of business system, standardization of and management, standardization of propaganda and development system, the company has improved the level of plasma station operation and management. At the same time, it has innovated the business model, actively built a local blood donation ecosystem, and improved the plasma collection capability; for new plasma stations, the company has adopted a flexible strategy of renting before building, and has optimized the standardized process of plasma station construction, effectively shortening the construction cycle, thereby accelerating the process of raw material collection. (4) Strong R&D Capability company has a strong technical force, undertaking more than 20 government special projects such as the "863 Program" project of the National and Jiangxi Province Major RD Special Projects, owning more than 200 various patents, and has won the Provincial and Municipal Science and Technology Awards and Excellent New Product Awards for many times. recent years, the company has continuously increased its R&D investment, and has successively launched PCC, factor VIII, highly concentrated intravenous immunoglobulin and other. The research projects such as tetanus immunoglobulin, C1 esterase, vWF factor, subcutaneous injection of human immunoglobulin, andalbumin are progressing smoothly. Among them, tetanus immunoglobulin has completed the listing application and is in the professional evaluation stage, forming a good product team in the and development, which will continue to optimize the company's product structure. In the future, the company will focus on the fields of small nucleic acids and gene therapy and deploy advance, further broadening the product structure and enhancing the company's core (5) Good production capacity The Company has a high level of quality management and is one of the first companies in China to the certification of the new version of GMP for Pharmaceutical Products. The Company adopts process automation control system to control the production process, and has realized the automatic recording of the whole processIP, SIP and key parameters. In accordance with the relevant laws and regulations and technical guidelines requirements, combined with the company's resource conditions, the Company has established a complete management system for pharmaceutical products, which ensures the continuous and stable production of pharmaceutical products that meet the intended use and registration requirements. The Company continues to optimize the production process, and core product collection rate is in the leading position in the industry, especially the fibrinogen prepared by the self-patented method, which is in the forefront of the collection rate market share. (6) Strong marketing capability In recent years, the Company has made significant progress in the construction of marketing team, commercial channel construction and academic promotion system. terms of team building, the Company has established a professional and market-oriented marketing team; in terms of academic promotion, it has basically covered the mainstream hospitals in the country, which strong support for the direct access of products to the terminal market; in terms of commercial channel construction, it has formed a strong combination and complementary advantages with the mainstream commercial. summary, the Company has obvious advantages in terms of the resource endowment and management empowerment of the controlling shareholder, clear strategic planning, excellent plasma station expansion and blood plasma collection capability, R&D capability, good production capacity and strong marketing capability. With the support of the controlling shareholders such as China Resources Group and China Resources Medical, the Company will continue to strive become a world-class blood products company and continuously promote the healthy development of the industry.competitiveness.